Skip to Main Content

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects (EMPA)

Conditions

Diseases of the Cardiovascular System

Phase I-II

What is the purpose of this trial?

The investigators propose a small pilot proof of concept study to not only prove the existence of, but also probe the mechanisms underlying cardio-renal effects of empagliflozin in patients with heart failure. The investigators propose a 50 patient randomized, double-blind, placebo-controlled crossover study with patients with stable HF, type II diabetes and an eGFR >45ml/min/1.73 m2 who are chronically receiving loop diuretics.

  • Trial with
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • Start Date
    04/18/2017
  • End Date
    10/30/2018
Trial Image

For more information about this study, contact:

Jennifer Tainsh

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    02/22/2018
  • Study HIC
    #2000020019